

**Suvorexant Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.11	16.10.2020	21516-00017	Date of first issue: 14.10.2014

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Suvorexant Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 855 Leandro N. Alem St., 8 Floor  
Buenos Aires, Argentina C1001AFB

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Short-term (acute) aquatic hazard : Category 2

Long-term (chronic) aquatic hazard : Category 3

**GHS label elements**

Hazard Statements : H401 Toxic to aquatic life.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**  
P273 Avoid release to the environment.  
**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

## Suvorexant Formulation

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
 Date of first issue: 14.10.2014

Chemical name	CAS-No.	Concentration (% w/w)
Suvorexant	1030377-33-3	>= 5 -< 10
Magnesium stearate	557-04-0	>= 1 -< 5

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
 Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.  
 Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
 Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
 Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.11	16.10.2020	21516-00017	Date of first issue: 14.10.2014

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
------------	---------	------------	-----------------	-------

## Suvorexant Formulation

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
 Date of first issue: 14.10.2014

		(Form of exposure)	ters / Permissible concentration	
Suvorexant	1030377-33-3	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	CMP	10 mg/m <sup>3</sup>	AR OEL
	Further information: A4 - Not classifiable as a human carcinogen, Irritation			
		TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

**Personal protective equipment**

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

**Filter type** : Particulates type

**Hand protection**

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

Viscosity, kinematic : Not applicable  
Explosive properties : Not explosive  
Oxidizing properties : The substance or mixture is not classified as oxidizing.  
Molecular weight : No data available  
Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.  
Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Components:****Suvorexant:**

Acute oral toxicity : LD50 (Rat): > 1.200 mg/kg  
LD50 (Dog): > 1.125 mg/kg  
LDLo (Mouse): 2.000 mg/kg

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials  
Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Remarks: Based on data from similar materials

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Rabbit  
Result : No skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Bovine cornea  
Result : Mild eye irritation  
Method : Bovine cornea (BCOP)

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Suvorexant:**

Test Type : Local lymph node assay (LLNA)  
Species : Mouse  
Assessment : Does not cause skin sensitization.  
Result : negative

**Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Suvorexant:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Test system: rat hepatocytes  
Result: negative

Test Type: Chromosomal aberration  
Test system: Chinese hamster ovary cells  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Result: negative

Test Type: Micronucleus test  
Species: Rat  
Result: negative

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Suvorexant:**

Species : Mouse  
Application Route : Oral  
Exposure time : 6 month(s)  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative



**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Reproductive toxicity**

Not classified based on available information.

**Components:****Suvorexant:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity Parent: NOAEL:  $\geq$  325 mg/kg body weight  
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 150 mg/kg body weight  
Result: negative

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 80 mg/kg body weight  
Result: negative

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT-single exposure**

Not classified based on available information.

**Components:****Suvorexant:**

Remarks : Based on human experience.

**STOT-repeated exposure**

Not classified based on available information.

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Components:****Suvorexant:**

Routes of exposure : Ingestion  
Target Organs : Central nervous system  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity****Components:****Suvorexant:**

Species : Rat  
NOAEL : 325 mg/kg  
LOAEL : 1.200 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Blood, Pancreas

Species : Dog  
NOAEL : 50 mg/kg  
LOAEL : 125 mg/kg  
Application Route : Oral  
Exposure time : 30 d  
Target Organs : Blood, Liver, Central nervous system

Species : Rat  
NOAEL : 75 mg/kg  
LOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 180 d  
Target Organs : Pancreas, Blood, Stomach

Species : Dog  
NOAEL : 50 mg/kg  
LOAEL : 125 mg/kg  
Application Route : Oral  
Exposure time : 270 d  
Target Organs : Blood

Species : Rat  
NOAEL : 40 mg/kg  
LOAEL : 80 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Eye, Central nervous system

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.11	16.10.2020	21516-00017	Date of first issue: 14.10.2014

---

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Suvorexant:

Ingestion : Symptoms: Drowsiness, Headache, abnormal dreams, Fatigue, Dizziness, dry mouth, Nausea, liver function change, upper respiratory tract infection, urinary tract infection, Cough, Diarrhea, Palpitation, tachycardia

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### Suvorexant:

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Mysidopsis bahia (opossum shrimp)): 0,56 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201  NOEC (Pseudokirchneriella subcapitata (green algae)): 2,5 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0,14 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0,5 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	:	EC50: > 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209  NOEC: 1.000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

## Suvorexant Formulation

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Magnesium stearate:**

- Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials
- Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.
- NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials
- Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

**Persistence and degradability****Components:****Suvorexant:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 81 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314
- Stability in water : Hydrolysis: < 10 %(5 d)  
Method: OECD Test Guideline 111

**Magnesium stearate:**

- Biodegradability : Result: Not biodegradable.  
Remarks: Based on data from similar materials

**Suvorexant Formulation**

Version 3.11      Revision Date: 16.10.2020      SDS Number: 21516-00017      Date of last issue: 23.03.2020  
Date of first issue: 14.10.2014

---

**Bioaccumulative potential****Components:****Suvorexant:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 358  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4,04

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil**

No data available

**Other adverse effects**

No data available

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

---

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

---

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.11	16.10.2020	21516-00017	Date of first issue: 14.10.2014

---

**International Regulations****The ingredients of this product are reported in the following inventories:**

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

---

**SECTION 16. OTHER INFORMATION****Further information**

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Full text of other abbreviations**

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AR OEL	:	Argentina. Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
AR OEL / CMP	:	TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB

## Suvorexant Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 23.03.2020
3.11	16.10.2020	21516-00017	Date of first issue: 14.10.2014

---

- Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8